KDMN

Kadmon Holdings

NYSE

Add Alert

KDMN

Kadmon Holdings

NYSE

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

farooq

10/21/21 9:10 AM

Post #70

Re: #68: @farooq - Here is a conservative play I am doing

Sold all between 9.38/9.39 not going to wait for extra 1%. now if there is some news than I could not find better take profit regret later.

farooq

10/18/21 3:28 PM

Post #69

What they are trying to pose deal in jeopardy by false lawsuits and attacking with low prices, most of the time doing short against box. What do you seriously think Sanofi bankers will let go there commission? They already bought enough shares to say yes. Weak hands will sell here or those who have stop losses. This decline tells me deal is near to close just after there Qtrly results.

farooq

10/18/21 12:48 PM

Post #68

Here is a conservative play I am doing in my SEP account and trading accounts.
I bought KDMN, right now it is 8.68/8.69 Low of the day. Company is already bought @ 9.50 cash, closing is in NOV/ December so you have chance to make 10% for about 2 months wait. I am uber long, right now 52500 share disclaimer. Most bought today because they wanted to pay least to options holders. They could be squeezed here.

farooq

09/10/21 9:24 AM

Post #67

Re: #66: @Jake L - KDMN - Bull Trap

It is already bought, What you are talking about?

Jake L

09/08/21 9:47 AM

Post #66

KDMN - Bull Trap

farooq

09/08/21 8:34 AM

Post #65

Re: #64: @farooq - Seems like so far MM covered there short

Bought out @ 9.50

farooq

08/18/21 11:45 AM

Post #64

Re: #63: @farooq - Holding Yesterdays break out. This week there could

Seems like so far MM covered there short options, so if the buyers wanted to hold it price action will be on upside. Other wise 4.50 could be in play again.
916000 shares needed to cover short option position which seems like they were able to do today.

farooq

08/12/21 4:11 PM

Post #63

Holding Yesterdays break out. This week there could be lots of action. MM could try to expire option 5 and above worth less or we see 7.69.

farooq

08/05/21 4:47 PM

Post #62

Re: #61: @farooq - NEW YORK, NY / ACCESSWIRE / August 5,

Kadmon Holdings, Inc.
Consolidated Statements of Operations - Unaudited
(in thousands, except share and per share data)

Three Months Ended Six Months Ended

June 30, June 30,

2021 2020 2021 2020
Revenues

Net sales
$ 24 $ 299 $ 384 $ 888
Other revenue
173 149 377 6,295
Total revenue
197 448 761 7,183
Cost of sales
11 162 107 490
Write-down of inventory
- 622 - 906
Gross profit
186 (336 ) 654 5,787
Operating expenses:

Research and development
18,525 16,516 33,799 29,390
Selling, general and administrative
13,656 10,068 26,252 19,434
Total operating expenses
32,181 26,584 60,051 48,824
Loss from operations
(31,995 ) (26,920 ) (59,397 ) (43,037 )
Total other income (expense)
1,650 (232 ) 674 (13,412 )
Income tax expense
- - - -
Net loss
$ (30,345 ) $ (27,152 ) $ (58,723 ) $ (56,449 )
Deemed dividend on convertible preferred stock
543 518 1,086 1,035
Net loss attributable to common stockholders
$ (30,888 ) $ (27,670 ) $ (59,809 ) $ (57,484 )

Basic and diluted net loss per share of common stock
$ (0.18 ) $ (0.17 ) $ (0.35 ) $ (0.36 )
Weighted average basic and diluted shares of common stock outstanding
171,967,623 162,416,059 171,829,335 161,101,923

Kadmon Holdings, Inc.
Condensed Consolidated Balance Sheets - Unaudited
(in thousands)

June 30, December 31,

2021 2020

Cash, cash equivalents and marketable debt securities
$ 270,494 $ 123,858
Other current assets
5,449 2,879
Investment, equity securities
10,815 10,564
Right of use lease asset
14,504 16,112
Other noncurrent assets
9,018 9,297
Total assets
$ 310,280 $ 162,710

Current liabilities
30,318 29,471
Lease liability - noncurrent
13,359 15,579
Other long term liabilities
233,148 1,637
Total liabilities
276,825 46,687
Total stockholders' equity
33,455 116,023
Total liabilities and stockholders' equity
$ 310,280 $ 162,710

Contact Information
833.900.5366
Investors@kadmon.com

SOURCE: Kadmon Holdings, Inc.

farooq

08/05/21 4:43 PM

Post #61

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021.
"The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."
Dr. Waksal added, "Our momentum continues as we advance our portfolio of product candidates. Initial data from our open-label, Phase 2 trial of belumosudil for the treatment of systemic sclerosis is anticipated by year-end 2021. The recent positive initial safety data presented at ASCO on KD033, our anti-PD-L1/IL-15 fusion protein, supports our confidence in the therapeutic potential of IL-15 for cancer. We look forward to sharing additional clinical data from this trial in the fourth quarter of 2021."
Second Quarter 2021 Results
Loss from operations for the three and six months ended June 30, 2021 was $32.0 million and $59.4 million, respectively, compared to $26.9 million and $43.0 million for the same period in 2020. The six months ended June 30, 2020 included $6.0 million in one-time license revenues related to the Meiji strategic partnership.
The $5.6 million and $11.2 million increase in operating expenses for the three and six months ended June 30, 2021, respectively, as compared to 2020 was primarily related to belumosudil commercial launch readiness activities, non-cash stock compensation expenses and direct external research and development costs of developing our preclinical product candidates from our immuno-oncology platform.
Liquidity, Capital Resources and Cash Runway
At June 30, 2021, the Company's cash, cash equivalents and marketable debt securities totaled $270.5 million, compared to $123.9 million at December 31, 2020. The Company expects its current financial position to be sufficient to fund its operations and capital expenditures into 2023.

farooq

08/03/21 12:21 PM

Post #60

Re: #59: @farooq - Seems like most of the shorts are covered

May revisit 3.95 if earnings do not show improvements.

farooq

08/02/21 1:47 PM

Post #59

Seems like most of the shorts are covered and it could be earning surprise coming. Hangs tight.

farooq

07/29/21 9:11 AM

Post #58

So MM shorted about 20 Millions share on the news total traded was about 28 millions shares on the news day, I think till they cover all it will in the range or until Reddit crowed start buying it. In that case 100+ price is also possible because of short interest.
Just dreaming, do not take seriously, hey some times dreams come true.

farooq

07/28/21 3:22 PM

Post #57

Re: #56: @farooq - Added 3500 near the close.

added more today @3.89 and 3.90.
It will be bought sooner big pharma won't let it become multi Billion $ company. Next earning in November they could be in black.

farooq

07/26/21 10:58 PM

Post #56

Re: #55: @saigai - 12,700...and my rosary beads

Added 3500 near the close.

saigai

07/22/21 12:05 PM

Post #55

12,700...and my rosary beads

farooq

07/22/21 11:59 AM

Post #54

Re: #52: @saigai - 2500 right here

Added today 3.77 to 3.83 now total 26000 plus long dated options less than 100.
Willing to buy 90,000 Common if price drop more. Buying in mostly cash account so no fear of margin call and not available for shorting.

farooq

07/22/21 11:55 AM

Post #53

Re: #50: @SurgeGuy2.0 - Fake News! Lolzzzz

You must be short.

saigai

07/20/21 1:19 PM

Post #52

2500 right here

Johnstonj27 PremiumMember

07/16/21 9:23 PM

Post #51

This one sure slipped through the radar... everyone was going to wait to move on it closer to Aug 30 and the FDA went full SNEAKER MODE... company got kind of screwed on FDA dropping it on a terrible DOW day with a BIO in index tanking.... Then a non-stop barcoding program killing all buying...

Amazing... sold when the BAR CODING went wide open... lately just crushing everything that trades with that crap. Frustrating.

SurgeGuy2.0 Free

07/16/21 6:35 PM

Post #50

Re: #48: @bUrRpPPP! - Approved..Congrats!

Fake News! Lolzzzz

farooq

07/16/21 4:39 PM

Post #49

I am in from 3.57 for 7300 shares, it is a lotto.

bUrRpPPP!

07/16/21 4:37 PM

Post #48

Approved..Congrats!

Johnstonj27 PremiumMember

07/16/21 4:31 PM

Post #47

And now the MM's are crashing it... Games Games Games

Johnstonj27 PremiumMember

07/16/21 4:03 PM

Post #46

wow, should held till afterhours they turned the barcoding diluter off they had on for the last 20 minutes of market hours... hate that crap where they trade between bid and Ask so nothing can go up....... been everywhere JULY... just retail doesn't stand a chance against that.

Johnstonj27 PremiumMember

07/16/21 3:33 PM

Post #45

Wow was scheduled for Aug 30 Date and gets released today? Wow

https://www.fdatracker.com/fda-calendar/

Johnstonj27 PremiumMember

07/16/21 3:20 PM

Post #44

Send it....

Johnstonj27 PremiumMember

07/16/21 3:20 PM

Post #43

FDA APPROVAL... halt is OFF

Johnstonj27 PremiumMember

07/16/21 3:18 PM

Post #42

BOOM FDA

Pennybuster Free

02/18/21 9:15 PM

Post #41

Adding

jerseyboy

12/27/20 12:31 AM

Post #40

Re: #39: @lakingsphan0427 - Lots of upgrades buy or strong buy on

This could have good long-term potential, but it may be overvalued at this point.

lakingsphan0427 Free

05/21/20 11:37 AM

Post #39

Lots of upgrades buy or strong buy on KDMN..

Just got on board hope this investment come into fruition..

ClayTrader Free

11/14/19 5:36 PM

Post #38

* * $KDMN Video Chart 11-14-19 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

11/12/19 5:27 PM

Post #37

* * $KDMN Video Chart 11-12-19 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

10/02/19 5:55 PM

Post #36

* * $KDMN Video Chart 10-02-2019 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

07/17/19 5:17 PM

Post #35

* * $KDMN Video Chart 07-17-2019 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

07/02/19 5:14 PM

Post #34

* * $KDMN Video Chart 07-02-2019 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

07/01/19 5:43 PM

Post #33

* * $KDMN Video Chart 07-01-2019 * *

Link to Video - click here to watch the technical chart video

ClayTrader Free

10/26/18 4:08 PM

Post #32

* * $KDMN Video Chart 10-26-18 * *

Link to Video - click here to watch the technical chart video

mcp4

10/17/18 2:22 PM

Post #31

KD025 just got Breakthrough Therapy Designation from the FDA. Breakthrough Therapy Designation is supposed to speed development and review of a drug used for a serious condition when early results show clinical improvement over existing therapies. Alas, it doesn't seem to do anything for the stock price.

mcp4

10/15/18 3:43 PM

Post #30

MetLife Investment Advisors has acquired 37K more shares of KDMN, at about $148K.

mcp4

10/10/18 3:57 PM

Post #29

Ouch. 52 week low. Not much news coming out except for some conference presentations.

mcp4

09/05/18 7:09 AM

Post #28

1.4M KDMN shares were just purchased by VHCP Management II. Other institutional investors taking a new position or adding to their current one include Dynamic Technology Lab Private, Citadel Advisors, Rhumbline Advisors, and DAFNA Capital Management.

Almost 70% of KDMN is owned by institutional investors.

mcp4

08/24/18 1:50 PM

Post #27

HC Wainwright has given KDMN a "Buy" rating with a $25 target price. Other analysts are not as optimistic. Zacks downgraded KDMN from a “buy” rating to a “hold” earlier this year.

mcp4

08/21/18 9:49 AM

Post #26

duplicate

mcp4

08/21/18 9:49 AM

Post #25

Zacks has rated Kadmon "buy" but contradicts their own "style score". When rated for Value, Growth and Momentum they rate KDMN an "F".

mcp4

08/15/18 2:26 PM

Post #24

New research paper is out regarding KD025, the ROCK2 inhibitor. "The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6."
Dinarello et al.
It's all lab bench type work that's not going to affect investor appeal but it's more supporting work for the pharmacology of KD025.

mcp4

08/09/18 6:36 PM

Post #23

2Q 2018 10-K is out.

87 pages is a lot to get through, but they are to build up inventory of KD034, their generic version of trientine hydrochloride. Kadmon has submitted 2 Abrreviated New Drug Applications with the FDA since it's chemically equivalent to the originally approved drug.

mcp4

07/03/18 12:02 PM

Post #22

Annual meeting announced for July 27th at the NY headquarters:
Schedule 14A

In other news the company completed a $113M public offering, and provided a positive update on the Phase II study of KD025 in cGVHD: ORR of >65%.